These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36564637)

  • 1. Censoring in the time trade-off valuation of worse-than-dead EQ-5D-5L health states: can a time-based willingness-to-accept question be the solution?
    Liao M; Rand K; Yang Z; Hsu CN; Lin HW; Luo N
    Qual Life Res; 2023 Apr; 32(4):1165-1174. PubMed ID: 36564637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
    Ludwig K; von der Schulenburg JG; Greiner W
    Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Censoring Time Trade-off Values at 0 Versus at -1: How Does the Assumption for Worse-Than-Dead Time Trade-off Values Affect the Modeling of EQ-5D-5L Valuation Data?
    Yang Z; Rand K; Luo N
    Value Health; 2023 May; 26(5):685-693. PubMed ID: 36375679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing "Pits" Time Trade-Off: Can Data Quality be Improved by Removing Death From Valuation of Health States?
    Liao M; Yang Z; Rand K; Luo N
    Value Health; 2024 Sep; 27(9):1261-1269. PubMed ID: 38795961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication.
    Chang JA; Hsu CN; Ramos-Goñi JM; Luo N; Lin HW; Lin FJ
    Eur J Health Econ; 2024 Aug; 25(6):1041-1055. PubMed ID: 38072877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How different are composite and traditional TTO valuations of severe EQ-5D-5L states?
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA
    Qual Life Res; 2016 Aug; 25(8):2101-8. PubMed ID: 26875190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
    Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
    Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
    Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
    Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study.
    Yang Z; Jiang J; Wang P; Wu J; Fang Y; Feng D; Xi X; Luo N
    Value Health; 2023 Jul; 26(7):968-973. PubMed ID: 36921897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EQ-5D-5L valuation study for Trinidad and Tobago.
    Bailey H; Jonker MF; Pullenayegum E; Rencz F; Roudijk B
    Health Qual Life Outcomes; 2024 Jul; 22(1):51. PubMed ID: 38956543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
    Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
    Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-revisiting the Utilities of Health States Worse than Dead: The Problem Remains.
    Jakubczyk M
    Med Decis Making; 2023; 43(7-8):875-885. PubMed ID: 37846095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preference heterogeneity in health valuation: a latent class analysis of the Peru EQ-5D-5L values.
    Karim S; Craig BM; Tejada RA; Augustovski F
    Health Qual Life Outcomes; 2023 Jan; 21(1):1. PubMed ID: 36593473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
    Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
    Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Graczyk K; Niewada M
    Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dutch Tariff for the Five-Level Version of EQ-5D.
    M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
    Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-Attribute Level Effects Models for Modeling Modified 5-Level Version of EQ-5D Health State Values: Is Less Still More?
    Yang Z; Rand K; Busschbach J; Luo N
    Value Health; 2023 Jun; 26(6):865-872. PubMed ID: 36566885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.